QC
CTMX icon

Quadrature Capital’s CytomX Therapeutics CTMX Stock Holding History

Quadrature Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-125,035
Closed -$399K – 1332
2025
Q3 		$399K Buy
+125,035
New +$282K ﹤0.01% 596

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Quadrature Capital's CTMX Position: Q4 2025 in Review

Quadrature Capital sold out of CytomX Therapeutics (CTMX) in Q4 2025, closing a stake of 125,035 shares — an estimated $399K sold.

Quadrature Capital first reported a position in CTMX in Q3 2025 and held it in 1 quarter. The position peaked at $399K in Q3 2025. 121 funds tracked by Wall St. Rank hold CTMX as of Q4 2025.

  • Quadrature Capital reported no remaining CytomX Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 125,035 CytomX Therapeutics shares in Q4 2025, an estimated $399K.
  • Quadrature Capital first reported a position in CytomX Therapeutics in Q3 2025 and held it in 1 quarter.
  • Quadrature Capital's CytomX Therapeutics position peaked at $399K in Q3 2025.
  • 121 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.